Full Press Release Details
Pharmaceuticals Commences Phase 2A Clinical Trials in
Begins Studies on its Oral Insulin Capsule at Hadassah Medical
Israel - April 14, 2008 - Oramed Pharmaceuticals, Inc., (OTCBB: ORMP,
www.oramed.com), a developer of oral delivery systems, commenced Phase 2A
studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem,
Israel yesterday. The Phase 2A trial is focused on assessing the safety and
efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study
is a continuation of the recently successfully completed Phase 1 studies in
pleased to have achieved this milestone of beginning Phase 2A clinical trials
Israel in the second quarter of this year," said Nadav Kidron, CEO of Oramed
Pharmaceuticals. "We have had much success with our past clinical trials, and
are on schedule with reaching our planned milestones and hope that Oramed's oral
insulin capsule will succeed in revolutionizing the current treatment for
Oramed Pharmaceuticals
Pharmaceuticals is an Israeli-based company focused on the development of oral
delivery solutions based on proprietary technology. Diabetes is one of the
rapidly growing diseases in the world and is one that requires constant and
often unpleasant monitoring and drug therapy regimens. Oramed is currently
developing an orally ingestible insulin capsule for the treatment of diabetes.
The company is also pursuing the development of oral delivery solutions for
other drugs and vaccines.
information please visit our website at: www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
Pharmaceuticals, Inc
Granito, Steven Melfi